Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $2.5 million.

  • Rani Therapeutics Holdings' Accounts Payables rose 5753.51% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 5753.51%. This contributed to the annual value of $1.4 million for FY2024, which is 10972.22% up from last year.
  • Latest data reveals that Rani Therapeutics Holdings reported Accounts Payables of $2.5 million as of Q3 2025, which was up 5753.51% from $1.8 million recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Accounts Payables high stood at $2.5 million for Q3 2025, and its period low was $506000.0 during Q2 2024.
  • For the 5-year period, Rani Therapeutics Holdings' Accounts Payables averaged around $1.4 million, with its median value being $1.4 million (2022).
  • As far as peak fluctuations go, Rani Therapeutics Holdings' Accounts Payables plummeted by 5561.64% in 2023, and later skyrocketed by 25533.6% in 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Accounts Payables (Quarter) stood at $1.1 million in 2021, then skyrocketed by 35.19% to $1.5 million in 2022, then plummeted by 55.62% to $648000.0 in 2023, then soared by 109.72% to $1.4 million in 2024, then surged by 81.53% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $1.8 million for Q2 2025, and $1.5 million during Q1 2025.